Showing results (1-10 of 44) with videos related to
Sort By:
Pageof 5
Cancer Research|September 18, 2014
Crosstalk between microRNA30a/b/c/d/e-5p and the canonical Wnt pathway: implications for multiple myeloma therapyJian-Jun Zhao, Ruben D CarrascoAnnual Review of Pathology|January 26, 2011
Pathogenesis of myelomaKenneth C Anderson, Ruben D CarrascoACS Nano|January 30, 2018
Nanoparticles for Immune Cytokine TRAIL-Based Cancer TherapyPedro P G Guimarães, Stephanie Gaglione, Tomasz Sewastianik, et al.The Journal of Investigative Dermatology|May 7, 2010
PD-1 on immature and PD-1 ligands on migratory human Langerhans cells regulate antigen-presenting cell activityVictor Peña-Cruz, Sean M McDonough, Felipe Diaz-Griffero, et al.Journal of Cutaneous Pathology|July 10, 2024
Primary cutaneous EBV+ extranodal NK/T-cell lymphoma of gamma/delta T-cell lineage in the posttransplantation settingJessica F Williams, Fabienne M Lucas, Ruben D Carrasco, et al.The American Journal of Dermatopathology|July 18, 2020
Aggressive CD4/CD8 Double-Negative Primary Cutaneous T-Cell Lymphoma With Dural Invasion: A Rare Presentation of Mycosis Fungoides?Koorosh Haghayeghi, Leslie Robinson-Bostom, Adam Olszewski, et al.Blood|December 10, 2013
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistanceZe Tian, Padraig D'Arcy, Xin Wang, et al.Blood|May 14, 2009
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cellsTeru Hideshima, Hiroshi Ikeda, Dharminder Chauhan, et al.Blood|March 10, 2009
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implicationsTeru Hideshima, Dharminder Chauhan, Tanyel Kiziltepe, et al.International Journal of Molecular Sciences|November 27, 2024
Characterization and Experimental Use of Multiple Myeloma Bone Marrow Endothelial Cells and ProgenitorsFilip Garbicz, Marcin Kaszkowiak, Julia Dudkiewicz-Garbicz, et al.Pageof 5